Jaguar Health (JAGX) Income from Continuing Operations (2014 - 2026)
Jaguar Health (JAGX) reported Income from Continuing Operations of 8723000.0 for Q1 2026, up 182.32% year-over-year from 3089717.8 in Q1 2025, and up 137.61% quarter-over-quarter from 23193000.0 in Q4 2025.
Jaguar Health (JAGX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 13 years of Income from Continuing Operations data on file, last reported at 8723000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 8723000.0, up 182.32% year-over-year; the trailing twelve-month figure through Mar 2026 was 34678000.0 (up 14.33% YoY), and the FY2025 annual result was 53997000.0, down 37.57% from the prior year.
- Income from Continuing Operations climbed to 8723000.0 in Q1 2026 per JAGX's latest filing, from 23193000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 8723000.0 in Q1 2026 and troughed at 23193000.0 in Q4 2025.
- A 5-year average of 10283588.24 and a median of 10021000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations slumped 126.63% in 2025, then soared 182.32% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 8232000.0 in 2022, then decreased by 13.08% to 9309000.0 in 2023, then declined by 9.94% to 10234000.0 in 2024, then tumbled by 126.63% to 23193000.0 in 2025, then surged by 137.61% to 8723000.0 in 2026.
- Business Quant data shows JAGX's Income from Continuing Operations at 8723000.0 in Q1 2026, 23193000.0 in Q4 2025, and 9648000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Jaguar Health | 1.44 Mn | -10.19 Mn | 19.11 Mn | 8.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.72 Mn |
| Dec 31, 2025 | -23.19 Mn |
| Sep 30, 2025 | -9.65 Mn |
| Jun 30, 2025 | -10.56 Mn |
| Mar 31, 2025 | -10.60 Mn |
| Dec 31, 2024 | -10.23 Mn |
| Sep 30, 2024 | -10.02 Mn |
| Jun 30, 2024 | -9.63 Mn |
| Mar 31, 2024 | -9.37 Mn |
| Dec 31, 2023 | -9.31 Mn |
| Sep 30, 2023 | -7.90 Mn |
| Jun 30, 2023 | -12.29 Mn |
| Mar 31, 2023 | -12.40 Mn |
| Dec 31, 2022 | -8.23 Mn |
| Sep 30, 2022 | -12.61 Mn |
| Jun 30, 2022 | -9.39 Mn |
| Mar 31, 2022 | -18.16 Mn |
| Dec 31, 2021 | -14.32 Mn |
| Sep 30, 2021 | -12.19 Mn |
| Jun 30, 2021 | -14.08 Mn |